Table 3 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors
收藏数据链接：
官方服务：
资源简介：
Patient disease status at diagnosis and study entry
创建时间：
2025-09-10
